Low vemurafenib plasma exposure as a short-term predictive parameter of progression disease in metastatic BRAFV600 mutated melanoma
Latest Information Update: 21 Jul 2015
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics; Therapeutic Use
- 21 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.